|
TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements. |
|
|
Stock and Other Ownership Interests - Rain Therapeutics |
Consulting or Advisory Role - AstraZeneca; Bayer; GreenPeptide; Ignyta; OncoMed; Rain Therapeutics; Roche/Genentech; Takeda |
Research Funding - Ignyta (Inst) |
Patents, Royalties, Other Intellectual Property - Licensing fees for biologic materials from Black Diamond (Inst); Licensing fees for biologic materials from Foundation Medicine (Inst); Licensing fees for biologic materials from Genentech (Inst); Licensing fees for patent from Rain Therapeutics; Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495; Licensing fees from Ignyta for biologic materials (Inst) |
Travel, Accommodations, Expenses - Ignyta; Rain Therapeutics; Roche/Genentech |
|
|
Honoraria - OncLive; Pfizer |
Consulting or Advisory Role - C4 Therapeutics; Genentech; Nuvalent, Inc. |
Research Funding - Hengrui Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Turning Point Therapeutics (Inst) |
Travel, Accommodations, Expenses - Pfizer |
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - Tempus |
|
|
Stock and Other Ownership Interests - TP Therapeutics; TP Therapeutics (I) |
Honoraria - AstraZeneca; Roche/Foundation Medicine; Roche/Genentech; Takeda |
Consulting or Advisory Role - AstraZeneca; Takeda; TP Therapeutics |
Speakers' Bureau - AstraZeneca; Roche/Foundation Medicine; Roche/Genentech; Takeda |
Travel, Accommodations, Expenses - AstraZeneca; Roche/Foundation Medicine; Roche/Genentech; Takeda; TP Therapeutics |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Epic Sciences |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Blueprint Medicines; Boehringer Ingelheim; G1 Therapeutics; Genentech/Roche; Loxo; Novartis; Takeda |
Research Funding - BeyondSpring Pharmaceuticals |
|
|
Stock and Other Ownership Interests - Healios |
Consulting or Advisory Role - Enlivity |
Patents, Royalties, Other Intellectual Property - Patent “glutamine & trehalose compositions Priority date 13-Sept 2013; ”App 14/470, 545 filed AUG 27, 2014 patent 61/878,084 issued Dec-26, 2017 |
Other Relationship - Enlivity |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche/Genentech |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Loxo; Merck Sharp & Dohme; Pfizer (Inst); Roche/Genentech |
Research Funding - Pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - Royalties from Veristrat (Biodesix); UpToDate |
|
|
Leadership - IGF Oncology; Martell diagnostic; Squarex Pharma; TTC Oncology; Vanquish Oncology |
Stock and Other Ownership Interests - Biothera; IGF Oncology; Vanquish Oncology |
Honoraria - EMD Serono; IGF Oncology; Martell diagnostic; Squarex Pharma; TTC Oncology; Vanquish Oncology |
Consulting or Advisory Role - TTC Oncology; Tychon |
Research Funding - Lilly (Inst); Merck (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Loxo (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Spectrum Pharmaceuticals (Inst); SWOG (Inst); TP Therapeutics (Inst) |
|
|
Employment - Turning Point Therapeutics |
Stock and Other Ownership Interests - Turning Point Therapeutics |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Bridgebio; Gencurix; Theravance |
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan |
Speakers' Bureau - Novartis |
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan |
Patents, Royalties, Other Intellectual Property - Champions Oncology |
|
|
Honoraria - Foundation Medicine; Medscape; MORE Health; OncLive; Peerview; PeerVoice; Physicans' Education Resource; Research to Practice; Targeted Oncology |
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Exelixis; Genentech/Roche; Helsinn Therapeutics; Hengrui Therapeutics; Ignyta; Lilly; Loxo; MORE Health; Pfizer; Takeda/Millennium; TP Therapeutics; Tyra Biosciences; Verastem; Verastem |
Research Funding - Foundation Medicine |
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology) |
Other Relationship - GlaxoSmithKline; Merck; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva |